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Abstract 
Purpose: To examine the prevalence and awareness of anabolic-androgenic steroid (AAS) use among 
male bodybuilders visiting gyms in Jazan region, Saudi Arabia. 
Methods: A cross-sectional survey was conducted among 500 male bodybuilders visiting gyms in the 
Jazan region of Saudi Arabia. Information on demographics, as well as the use of AAS, was included in 
a self-administered questionnaire.  
Results: The prevalence of AAS in Jazan was 31.0 % (95 % CI, 26.9 - 49.6), and it was higher among 
those in the 30 - 34 years 45.3 % (95 % CI, 36.9 - 54.0). Its prevalence was also significantly higher 
among athletes who received higher education 37.4% (95 % CI, 31.8 - 43.4). The most common types 
of AAS used are Deca-Durabolin (57.6 %) and testosterone (52 %). Thirty percent of the participants 
who used AAS suffered from depression and aggressive behavior while 18 % of them were 
hypertensive. The participants were not well aware of the adverse effects of anabolic steroids use. 
Conclusion: The prevalence of the anabolic steroids is high among bodybuilding males visiting gyms in 
Jazan region, Saudi Arabia. Health educational programs are required to increase the awareness about 
the side effects of anabolic steroids among bodybuilders. 
 
Keywords: Anabolic steroids, Bodybuilders, Deca-durabolin, Testosterone 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Anabolic-androgenic steroids (AAS) are a type of 
synthetic steroid hormones related to the 
hormone testosterone [1,2]. These drugs are 
available by prescription and used to treat cases 
caused by an abnormal low production of 
testosterone, such as delayed puberty and 
impotence [1].  
 
Serious side effects are noted among users of 
anabolic steroids. These include increase 
aggressiveness, euphoria, diminished fatigue, 
increased libido, and mood swings [3]. The side 
effects also comprise high blood pressure, liver 
tumors and cancers, fluid retention, and jaundice 
[1]. Other side effects include severe acne, 
kidney tumors and tremors [4]. In men, AAS can 
even cause shrinking of testicles, development of 
breasts and prostate cancers, baldness, reduced 
sperm count, and infertility [4-6]. 
 
Hall and Hall (2005), in their review, suggested 
that anabolic steroid abuse has become a major 
problem in the United States, with more than 1 
million individuals abusing these drugs [7]. 
Another study conducted among health club 
users in the South Wales area revealed that AAS 
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use is prevalent (70 %) among recreational gym 
users [8]. Studies regarding the prevalence of 
AAS use among adolescents reported lifetime 
prevalence ranging from 1 % to 5 % [9]. 
 
In the Middle East, the number of gym users 
taking anabolic steroids is steadily increasing. 
Recent studies in Jordan found that 26 % of 
bodybuilders reportedly used anabolic steroids 
[10]. The use of anabolic steroids among gym 
users in United Arab Emirates was estimated at 
22 % [2] while AAS use among Iranian youths 
training to be bodybuilders was about 13 % [11]. 
In Kuwait, 22.7 % of the general population and 
4.2 % of college students are AAS users [12].  
 
Evidence suggests that an increasing number of 
deaths of athletes in the age group of 20 - 30 
years is due to heart diseases resulting from 
AAS use [13]. AAS are toxic to the cardiac tissue 
and leads to cardiomyopathy with impaired 
systolic and diastolic functions [14,15]. The use 
of AAS also leads to increased LDL and 
decreased HDL in the blood, which represents a 
great risk for coronary heart disease [4,16-18]. 
There are still a limited number of studies 
suggesting AAS-induced atherosclerosis [19,20]. 
 
Exogenous AAS use disturbs the hypothalamic-
pituitary-testicular (HPT) axis in males [21]. They 
become hypogonadal when they stop using 
anabolic steroids abruptly after prolonged use 
[21]. Active oral AAS can cause hepatotoxicity 
and hepatic neoplasms [22].  Prostate 
hypertrophy with an increased risk of prostate 
cancer can also occur with prolonged use of AAS 
[23-25]. Other resulting psychiatric disorders 
include psychosis, hypomania, and severe 
depression [24-26]. 
 
It should be noted that no previous study was 
conducted on the use of anabolic steroids among 
male bodybuilders using gym facilities in Jazan, 
Saudi Arabia. The main objective of this paper is 
to estimate the prevalence of anabolic steroid 
and its awareness among male bodybuilders 




Study design and setting 
 
An observational cross-sectional survey was 
conducted in the Jazan region. Jazan (or Gizan) 
region lies in the southwest corner of Saudi 
Arabia, north of the border with Yemen; the 
region is sub-divided into 14 governorates. The 
region is one of the 13 regions comprising the 
Kingdom of Saudi Arabia and has a population of 
approximately 1.5 million. 
Sampling procedure 
 
Using the statistical formula for cross-sectional 
study design, the sample size for this study was 
estimated to be 500 participants. The calculation 
was based on the prevalence of AAS = 50 %, 95 
% confidence interval (CI), error below 5 %, and 
a non-response rate of 25 %. The research team 
excluded the governorates that did not have any 
gym facilities. After exclusion, we ended up with 
six governorates. We, then, randomly selected 
one gym from each selected governorate. The 
selected governorates were Sabya, Samtah, Abu 
Arish, Jazan, Baish, and Ahad AL-Masaraihah. 
The final sample size was distributed among the 
selected gyms proportionate to the actual 
bodybuilders’ size in each gym. In each selected 
gym, the study participants were identified using 
systematic random sampling. 
 
Data collection  
 
A self-administered questionnaire was used for 
data collection. The questionnaire was designed 
after consulting a number of previous studies 
conducted in the same domain [2,12]. The final 
version of the questionnaire involved 
approximately 50 multiple-choice questions. The 
questions included sections on background 
characteristics of study participants, types of 
AAS used, reported side effects, and questions 





The statistical analysis was performed using 
SPSS ver. 20.0 (SPSS Inc. Chicago, IL, USA) 
software. The prevalence of anabolic steroid use 
among the study subjects was calculated using 
95 % confidence intervals (CI). The Chi-square 
test/ Fisher’s exact test was used to evaluate the 
prevalence of use among the different sub-
groups. The p value less than 0.05 was used to 
indicate statistical significance.  
 
Ethical considerations  
 
Ethical approval for this study was obtained from 
the College of Medicine, Jazan University, Jazan. 
Saudi Arabia (approval no. CLC 432-2015/2016 
Module). Participants signed the study consent 
before answering the survey questionnaire. It 
was made clear to all participants that they had 
the right to not participate in the study or 
withdraw from the survey at any time if they 
wished to do so. Also, subjects’ privacy was 
ensured at all study stages. The survey data was 
kept confidential and utilized for study purposes 
only and the whole ethics procedures is 
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conducted in accordance with the International 
ethical guidelines for biomedical research 




A total of 500 questionnaires were distributed 
among male bodybuilders visiting gyms. A total 
of 465 questionnaires were included in the final 
analysis (93 %), and the rest of the 
questionnaires (7 %) were excluded from the 
study due to non-response. Table 1 shows the 
demographic characteristics of the study 
population. According to the table, more than 50 
% of the study participants received higher 
education. The majority of male bodybuilders 
were between 20 - 34 years, which represented 
approximately 80 % of the total. About 42 % of 
the samples were students, and 45 % were 
employed. Forty percent of the samples have a 
monthly income between $261 and $1333, and 
about 25 % drew income less than $260. 
 
Table 1: Background characteristics of the study 
population (n = 465) 
 
Characteristic N % 
Level of education  
Basic education 205 44.1 
Higher education  260 55.9 
Age group (years)  
15-19 68 14.6 
20-24 140 30.1 
25-29 96 20.6 
30-34 128 28 
>34  33 7.1 
Occupation  
Unemployed  60 12.9 
Student  194 41.7 
Employed  211 45.4 
Monthly income ($)  
< 260 118 25.4 
261 - 1333 185 39.8 
1334 - 2765 89 21.1 
> 2766 61 13.1 
 
Table 3 shows that AAS use is significantly 
higher among male bodybuilders (38.7 %) 
compared with other sports. AAS use was very 
high (46.7 %) and significantly different among 
participants who used gym for a period of one to 
less than two years. AAS use is positively 
associated with the duration of gym use per hour 
(p value 0.001). AAS use is also positively 
associated with frequency of gym use per week 
but with no significant association (p value 
0.302). 
According to Table 4, the most common types of 
AAS used are Deca-Durabolin (57.6 %) and 
testosterone (52 %). Bodybuilders usually use 
AAS as a course for a predefined period of time. 
The course usually has more than one type of 
steroid as mentioned in Table 4. The same table 
illustrates the route of administration of AAS. 
Thirty-eight percent of the users use needle or 
injections, 27 % use oral steroids while 35 % use 
both needles and oral steroids. Twenty-seven 
percent of the participants who used AAS 
reported depression and aggressive behavior 
while 36 % of them demonstrated hypertension. 
More than 35 percent of them had been using 
steroids for less than a year while 15.3% of them 
had been using steroids for two years and more. 
 
According to Figure 1, 56 % of the participants 
agreed that anabolic steroids can cause side 
effects while 58.6 % of them believed that AAS 
use has a beneficial effect on them. Sixty-one 
percent of the participants had no knowledge 
about the sexual problems arising out of AAS 
use. Thirty-one percent of the participants knew 
that AAS can increase blood pressure while 47 
% of them knew about the behavioral changes 




This study shows the prevalence of AAS use 
among male bodybuilders visiting gyms in the 
Jazan region. The prevalence of AAS users in 
Jazan region was as high as 31 %. The 
comparison of our findings with the studies 
conducted in different countries reveals a 
shocking conclusion: the abuse of AAS in the 
Jazan region was more than double the 
prevalence of AAS use among Iranian 
bodybuilders (13 %) [11]. Also, AAS use was 
much higher than that reported in similar studies 
conducted in Kuwait (22 %) and United Arab of 
Emirates (22 %) [2,12]. The prevalence of AAS 
use among gym users in Jazan region was very 
high. A possible explanation for this is the 
competition among gym users to build muscles 
over a short span of time. Another reason could 
be the absence of awareness programs among 
the gym users. 
 
The highest prevalence (45.3 %) of AAS usage 
was among the 30-34 age. This result is different 
from what was reported in Kuwait and Middle 
East and North Africa (MENA) region studies 
[12]. The highest prevalence of AAS use in 
Kuwait was among the age group of 19-25 years 
was (46.8 %), which was similar to that reported 
in the MENA region.  
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Table 2: Prevalence of anabolic steroid use according to selected characteristic, Jazan, KSA (n = 465) 
 
Characteristic Users/Total Prevalence 95% CI P-value 
Level of education    
0.001 Basic education 46/203 22.7 17.4-28.9 
Higher education 98/262 37.4 31.8-43.4 
Age group (years)    
<0.001 
15- 19 12/68 17.6 10.4-28.4 
20-24 30/140 21.4 15.5-29.0 
25-29 37/96 38.5 29.4-48.6 
30-34 58/128 45.3 36.9-54.0 
                >34 7/33 21.2 10.7-37.9 
Occupation    
0.009 
Unemployed 22/60 36.7 25.6-49.4 
Student 45/194 23.2 17.8-29.6 
Employed 77/211 36.5 30.3-43.2 
Monthly income ($)    
0.028 
< 260 30/118 25.4 18.4-34.0 
261 - 1333 49/185 26.5 20.7-33.3 
1334 - 2765 42/100 42.0 32.8-51.8 
> 2766 23/62 37.1 26.1-49.6 
Overall prevalence 144/465 31.0 26.9-49.6  
 




AAS use P-value  
 Yes, N(%) No, N(%) 
Type of exercise 
<0.001 
 
Bodybuilding 138(38.7) 219(61.3) 
Swimming  0 10(100) 
Fitness  3(4.2) 69(95.8) 
Martial art  3(11.5) 23(88.5) 
Gym use duration  
 
<0.001 
< 6 months  6(5.6) 101(94.4) 
6 to < 12 months  41(31.3) 90(68.7) 
12 to 24 months  57(46.7) 65(53.3) 
≥ 24 months 40(38.5) 64(61.5) 




< 1 h 76(26.9) 207(73.1) 
1 to < 2 h 40(31.5) 87(68.5) 
≥ 2 h 28(52.8) 25(47.2) 




Once 4(17.4) 19(82.6) 
Twice  2(22.2) 7(77.8) 
Three times 16(23.9) 51(76.1) 
Four times 52(32.9) 106(67.1) 
Five times and more 70(33.7) 138(66.3) 
Most of our study participants had information 
about AAS benefits (e.g. increasing muscle size 
and endurance), but their knowledge about the 
side effects of AAS was very low. This explains 
the lack of public awareness about the risk of 
AAS use. Interestingly, our study revealed that 
there is a significant association between AAS 
use and high level of education. The prevalence 
of AAS use was higher among bodybuilders who 
received higher education, which means that 
awareness is independent of AAS use. Other 
studies concluded that spreading awareness 
about the side effects of AAS may not be the 
only effective strategy for limiting their abuse 
[12]. 
Limitations of the study 
 
The study had few limitations. First, the research 
team did not ask for more details about the 
content and dose of AAS. Second, the study 
utilized a self-administered questionnaire to 
collect data on AAS use and their side effects. 
No other confirmation method was used to 
document AAS use among study participants. 
Finally, the study was based on a cross-sectional 
study design, which is not appropriate for 
assessing associations, and the causal 
relationships between the variables cannot be 
established properly.  
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Table 4: Pattern of AAS use among male 
bodybuilders visiting gyms and reported side effects 
 
Characteristic No. of users (%)* 
Brand (generic name)   
Testosterone (Enanthate) 54 37.5  
Anvar (oxandrolone) 38 26.3  
Winstrol (stanozolol) 25 17.3  
Testosterone (Varies) 75 52.0  
Deca-Durabolin (drolonedecanoate) 83 57.6  
Primobolan 24 16.6  
Route of administration   
Needle or injections 55 38.2 
Use oral steroids 39 27.1 
Both needles and oral steroids.  50 34.7 
Side effects   
Any side effect 46 31.9 
depression and aggressive 39 27.1 
hypertension 25 36.0 
Duration of use   
Less than 6 months  38 26.4 
6 months to less than one  51 35.4 
One year to less than two  33 22.9 
Two years and more 22 15.3 
*Percentage totals more than 100% due to use of 
multiple anabolic androgenic steroids by gym-athletes 
 
 
Figure 1: Correct response on knowledge about AAS 




The prevalence of anabolic steroid use is high 
among male bodybuilders visiting gyms. The 
most common types of AAS used are Deca-
Durabolin and testosterone. It is highly 
recommended that Regional Health Authorities 
in Jazan region should increase awareness and 
knowledge about the side effects of anabolic 
steroids’ use. This can be achieved by 
distributing leaflets that explain the serious side 
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